RESEARCH PAPER

Next-Generation Strategies in Anticancer Drug Design: Future Outlook

[1]Saloni Fakroddin Mulani*, [2]Dr. Sachin K. Bhosale, [3]Dr. Ushir Y.V., [4]Dr. Nirmala V. Shinde,

[1] Research Scholar, Department of Pharmaceutical Chemistry, Savitribai Phule Pune University, S.M.B.T. College of Pharmacy, Dhamangaon, Nashik, Maharashtra, India.
[2,4]Associate Professor, Department of Pharmaceutical Chemistry, Savitribai Phule Pune University, S.M.B.T. College of Pharmacy, Dhamangaon, Nashik, Maharashtra, India.
[3]Principal, Department of Pharmaceutical Chemistry, Savitribai Phule Pune University, S.M.B.T. College of Pharmacy, Dhamangaon, Nashik, Maharashtra, India.
[1]*salonimulanivncop@gmail.com,* [2]*sachiniper@rediffmail.com,* [4]*nirmalampharm@rediffmail.com*

Received: 16th Dec, 2025; Revised: 8th Feb 2026; Accepted: 24th Feb, 2026; Available Online: 30th March, 2026

ABSTRACT
Cancer remains one of the leading causes of mortality worldwide, necessitating the continuous evolution of effective therapeutic strategies. Traditional chemotherapy, although effective, is often associated with systemic toxicity and drug resistance. Recent advancements in computational tools, molecular biology, and nanotechnology have revolutionized anticancer drug design. Techniques such as Quantitative Structure–Activity Relationship (QSAR), molecular docking, artificial intelligence (AI), and targeted drug delivery systems are enabling the development of more selective and potent anticancer agents. This review highlights emerging strategies in anticancer drug discovery, focusing on computational approaches, multi-target drug design, nanocarrier-based delivery, and personalized medicine. The integration of these approaches offers a promising future for developing safer and more effective cancer therapies.
Keywords: Anticancer agents, QSAR, Molecular docking, Drug design, Nanotechnology, Personalized medicine
How to cite this article: Mulani SF, Bhosale SK, Ushir YV, Shinde NV. Next-Generation Strategies in Anticancer Drug Design: Future Outlook. Int J Drug Deliv Technol. 2026;16(24s): 629-636. DOI: 10.25258/ijddt.16.24s.79
Source of support: Nil.
Conflict of interest: None

1. INTRODUCTION

Cancer is a complex and multifactorial disease [6].characterized by uncontrolled cell proliferation and metastasis. Despite significant progress in treatment, challenges such as drug resistance, toxicity, and lack of selectivity [9]persist. Conventional drug discovery approaches are time-consuming and costly. Therefore, modern research is shifting towards computationally driven and target-specific strategies to accelerate drug development and improve therapeutic outcomes [7,8].

2. LIMITATIONS OF CONVENTIONAL ANTICANCER THERAPIES

Despite significant advancements in cancer treatment, conventional anticancer therapies such as chemotherapy, radiotherapy, and surgery are associated with several critical limitations that hinder their overall effectiveness and patient outcomes.

1. Lack of Selectivity

One of the major drawbacks of traditional chemotherapy is its **non-selective mechanism of action**. Most anticancer drugs target rapidly dividing cells without distinguishing between cancerous and normal cells. As a result, healthy cells in tissues such as bone marrow, gastrointestinal tract, and hair follicles are also affected, leading to severe side effects.

2. Systemic toxicity [10] and Side Effects

Conventional therapies often cause **dose-limiting toxicities**, including:

- Nausea and vomiting
- Hair loss (alopecia)
- Myelosuppression (reduced blood cell production)
- Organ toxicity (liver, kidney, heart)

These adverse effects significantly reduce patient quality of life and may require dose reduction or discontinuation of therapy.

3. Development of Drug Resistance

Cancer cells can develop **resistance to anticancer drugs** through various mechanisms such as:

- Overexpression of drug efflux pumps (e.g., P-glycoprotein)
- Mutation of drug targets
- Enhanced DNA repair mechanisms
- Alteration in apoptotic pathways

This resistance reduces the long-term effectiveness of treatment and leads to disease relapse.

4. Poor bioavailability [12] and Solubility

Many anticancer drugs suffer from **low aqueous solubility and poor bioavailability**, which limits their absorption and distribution in the body. This results in:

- Reduced therapeutic efficacy
- Need for higher doses
- Increased risk of toxicity

5. Non-Specific Distribution

Conventional drugs are distributed throughout the body, leading to **non-specific targeting**. This causes:

- Damage to healthy tissues
- Reduced drug concentration at the tumor site
- Lower therapeutic efficiency

6. Tumor Heterogeneity

**Author for Correspondence: salonimulanivncop@gmail.com*

Tumors are highly heterogeneous, consisting of different populations of cancer cells with varying genetic and phenotypic characteristics. Conventional therapies often fail to target all subpopulations effectively, resulting in:

- Partial treatment response
- Tumor recurrence

7. Limited Effectiveness Against Metastasis

Metastatic cancer, where cancer spreads to distant organs, remains difficult to treat with conventional therapies. These treatments are often less effective in eliminating **secondary tumor sites**, leading to poor prognosis.

8. High Cost and Treatment Burden

Cancer treatment is often expensive and requires prolonged therapy cycles. Hospitalization, supportive care, and management of side effects increase the overall **economic burden** on patients and healthcare systems.

9. Poor Patient Compliance

Due to severe side effects, long treatment duration, and frequent hospital visits, patient compliance is often reduced, which negatively impacts treatment outcomes.

These limitations highlight the need for **next-generation drug design approaches**.

3. COMPUTATIONAL APPROACHES IN DRUG DESIGN

3.1 QSAR Modeling [13–15]

Introduction

Quantitative Structure–Activity Relationship (QSAR) modeling is a powerful computational technique used in modern drug design to establish a mathematical relationship between the **chemical structure of compounds and their biological activity**. It plays a crucial role in predicting the activity of new molecules before synthesis, thereby reducing time, cost, and experimental effort.

Principle of QSAR

QSAR is based on the assumption that **structural features of molecules influence their biological activity**. By analyzing physicochemical, electronic, and steric properties of compounds, QSAR models correlate these descriptors with observed biological responses such as anticancer activity.

Types of QSAR Models

- **2D-QSAR:**
  Uses molecular descriptors such as hydrophobicity (log P), molecular weight, and electronic parameters.
- **3D-QSAR:**
  Considers three-dimensional properties like steric and electrostatic interactions (e.g., CoMFA, CoMSIA).
- **4D/5D-QSAR:**
  Incorporates conformational flexibility and environmental factors for more accurate predictions.

QSAR Workflow

1. Selection of dataset (compounds with known activity)
2. Molecular structure optimization
3. Calculation of descriptors
4. Model building using statistical methods (MLR, PLS, ANN)
5. Validation of model (R^2, Q^2, RMSE)
6. Prediction of activity of new compounds

Applications in Anticancer Drug Design

- Identification of **lead compounds**
- Optimization of chemical structures
- Prediction of **cytotoxic activity**
- Reduction in experimental screening
- Designing molecules with improved **selectivity and potency**

Advantages of QSAR

- Cost-effective and time-saving
- Reduces need for extensive biological testing
- Helps in rational drug design
- Facilitates virtual screening of large compound libraries

Limitations of QSAR

- Dependent on quality and size of dataset
- May not account for complex biological interactions
- Limited predictability outside training dataset
- Requires careful validation

3.2 Molecular Docking [16–18]

Introduction

Molecular docking and simulation are essential computational techniques used in modern drug discovery to predict the interaction between a **ligand (drug molecule)** and a **target protein**. These approaches help in understanding binding affinity, orientation, and stability of drug–target complexes, thereby facilitating rational drug design.

Principle

Molecular docking predicts the **preferred orientation of a ligand** when it binds to the active site of a target protein. The goal is to identify the most stable complex with **minimum binding energy**.

Docking algorithms evaluate:

- Shape complementarity
- Hydrogen bonding interactions
- Hydrophobic interactions
- Electrostatic forces

Types of Docking

- **Rigid Docking:**
  Both ligand and protein are treated as rigid structures.
- **Flexible Docking:**
  Ligand flexibility (and sometimes protein flexibility) is considered, providing more realistic results.

Docking Workflow

1. Selection of target protein (from Protein Data Bank)
2. Preparation of protein (removal of water molecules, addition of hydrogen atoms)
3. Ligand preparation and optimization
4. Active site identification
5. Docking simulation using software (e.g., AutoDock, Glide)
6. Scoring and ranking of binding poses
7. Visualization of interactions

Applications in Anticancer Drug Design

- Identification of **binding interactions with cancer targets**
- Screening of large compound libraries
- Lead optimization based on binding affinity

- Understanding mechanism of action

Molecular Dynamics (MD) Simulation

Principle

Molecular dynamics simulation studies the **time-dependent behavior of the ligand–protein complex** under physiological conditions. It provides insights into the **stability and conformational changes** of the system.

Key Parameters Analyzed

- **RMSD (Root Mean Square Deviation):** Stability of the complex
- **RMSF (Root Mean Square Fluctuation):** Flexibility of residues
- **Hydrogen bond interactions:** Stability of binding
- **Radius of gyration:** Compactness of protein
- **Energy profiles:** System stability over time

Applications

- Validation of docking results
- Understanding dynamic behavior of complexes
- Predicting long-term stability of drug binding
- Refinement of lead compounds

Advantages

- Provides detailed molecular-level insights
- Reduces experimental cost and time
- Enhances accuracy of drug design
- Helps in predicting binding stability

Limitations

- Dependent on accuracy of protein structure
- Computationally intensive (especially MD simulations)
- Results may vary with software and parameters
- Requires experimental validation

3.3 Artificial Intelligence and Machine Learning [19–23]

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative tools in modern drug discovery. These technologies enable the analysis of large and complex biological datasets to identify patterns, predict outcomes, and accelerate the development of novel anticancer agents. AI-driven approaches significantly reduce the time, cost, and failure rates associated with traditional drug discovery processes.

Basic Concepts

- **Artificial Intelligence (AI):**
  Refers to computational systems capable of performing tasks that typically require human intelligence, such as decision-making, pattern recognition, and prediction.
- **Machine Learning (ML):**
  A subset of AI that uses algorithms to learn from data and improve performance without explicit programming.

Types of Machine Learning in Drug Discovery

- **Supervised Learning:**
  Uses labeled datasets to predict outcomes (e.g., activity prediction of compounds).
- **Unsupervised Learning:**
  Identifies hidden patterns or clusters in data (e.g., compound classification).
- **Reinforcement Learning:**
  Learns optimal strategies through trial and error, useful in drug optimization.

Applications in Anticancer Drug Design

1. Drug Target Identification

AI helps identify novel cancer-related targets by analyzing genomic and proteomic data.

2. Lead Compound Discovery

ML models can screen large chemical libraries and predict potential **anticancer compounds** with high accuracy.

3. QSAR and Activity Prediction

AI enhances QSAR modeling by improving prediction accuracy using advanced algorithms such as neural networks and random forests.

4. Molecular Docking Optimization

AI can refine docking results by predicting binding affinity and improving scoring functions.

5. De Novo Drug Design

AI algorithms generate **new molecular structures** with desired biological properties.

6. Prediction of ADMET Properties

AI models predict:

- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity

This helps in early identification of safe drug candidates.

Advantages

- Rapid analysis of large datasets
- High prediction accuracy
- Reduction in experimental workload
- Accelerates drug discovery process
- Enables personalized medicine

Limitations

- Requires large, high-quality datasets
- Risk of model overfitting
- Limited interpretability of some models
- Requires computational expertise

4. TARGETED THERAPY AND PRECISION MEDICINE [24–27]

Targeted therapies focus on specific molecular targets involved in cancer progression, such as receptors, enzymes, and signaling pathways. Precision medicine tailors treatment based on genetic and molecular profiles of patients, improving therapeutic efficacy and reducing adverse effects.

Targeted therapy and precision medicine represent advanced approaches in cancer treatment that aim to improve therapeutic efficacy while minimizing adverse effects. Unlike conventional chemotherapy, which affects both normal and cancerous cells, these strategies focus on **specific molecular targets and patient-specific characteristics**, leading to more effective and safer treatments.

Targeted Therapy

Targeted therapy involves the use of drugs designed to specifically interact with **molecular targets** such as

proteins, enzymes, or receptors that are overexpressed or mutated in cancer cells. These targets play a key role in tumor growth, survival, and metastasis.

Types of Targeted Therapies

- **Small Molecule Inhibitors:** Block intracellular signaling pathways (e.g., tyrosine kinase inhibitors)
- **Monoclonal Antibodies:** Bind to extracellular receptors or antigens on cancer cells
- **Hormonal Therapies:** Target hormone-dependent cancers (e.g., breast cancer)
- **Immune-Targeted Therapies:** Enhance immune system recognition of cancer cells

Mechanism of Action

- Inhibition of cell proliferation signals
- Induction of apoptosis (programmed cell death)
- Blocking angiogenesis (blood vessel formation)
- Interference with metastasis pathways

Advantages

- High specificity toward cancer cells
- Reduced damage to normal tissues
- Improved therapeutic outcomes
- Fewer side effects compared to chemotherapy

Limitations

- Development of resistance
- High cost of treatment
- Limited applicability to certain cancer types
- Requires identification of suitable molecular targets

Precision Medicine

Precision medicine, also known as personalized medicine, involves tailoring treatment based on an individual patient's:

- Genetic profile
- Molecular characteristics of the tumor
- Environmental and lifestyle factors

Key Components

- **Biomarker Identification:** Detecting specific genes or proteins associated with cancer
- **Genomic Profiling:** Understanding mutations and variations in tumor DNA
- **Patient Stratification:** Grouping patients based on predicted treatment response

Applications in Cancer Therapy

- Selection of the most effective drug for a patient
- Avoidance of ineffective treatments
- Optimization of drug dosage
- Monitoring treatment response

Integration of Targeted Therapy and Precision Medicine

The combination of targeted therapy with precision medicine enables:

- Development of **patient-specific treatment strategies**
- Improved clinical outcomes
- Reduction in trial-and-error prescribing

5. MULTI-TARGET DRUG DESIGN [28–30]

Traditional drug discovery has largely focused on the **"one drug–one target–one disease"** paradigm. However, cancer is a highly complex and multifactorial disease involving multiple signaling pathways and molecular mechanisms. This complexity often limits the effectiveness of single-target drugs. Therefore, **multi-target drug design** has emerged as a promising strategy to improve therapeutic efficacy and overcome drug resistance.

Concept of Multi-Target Drug Design

Multi-target drug design involves the development of a **single molec**

ule capable of interacting with multiple biological targets simultaneously. These targets may include enzymes, receptors, signaling proteins, or transcription factors involved in cancer progression.

Rationale in Cancer Treatment

Cancer involves multiple pathways such as:

- Cell proliferation
- Apoptosis evasion
- Angiogenesis
- Metastasis

Targeting a single pathway may not be sufficient; hence, multi-target drugs can:

- Disrupt several pathways at once
- Prevent compensatory mechanisms
- Enhance therapeutic outcomes

Strategies for Multi-Target Drug Design

1. Linked Pharmacophores

Combining two or more active pharmacophores into a single molecule to target different sites.

2. Hybrid Molecules

Fusion of two bioactive compounds into one structure with dual or multiple functions.

3. Privileged Structures

Use of chemical scaffolds capable of binding to multiple targets.

4. Network Pharmacology Approach

Understanding biological networks and designing drugs that modulate multiple nodes within the network.

Applications in Anticancer Drug Design

- Simultaneous inhibition of multiple cancer pathways
- Overcoming multidrug resistance
- Improved efficacy in complex tumors
- Reduced need for combination therapy

Advantages

- Enhanced therapeutic effectiveness
- Reduced drug resistance
- Lower risk of treatment failure
- Potential reduction in drug dosage

Challenges

- Difficulty in optimizing selectivity for multiple targets
- Increased risk of off-target effects
- Complex pharmacokinetic and pharmacodynamic profiles
- Challenging synthesis and design

6. NANOTECHNOLOGY-BASED DRUG DELIVERY [31–34]

Nanotechnology-based drug delivery systems have revolutionized cancer treatment by enabling **targeted, controlled, and efficient delivery of anticancer agents**. These systems utilize nanoscale carriers (1–100 nm) to improve the pharmacokinetic and

pharmacodynamic profiles of drugs, particularly those with poor solubility and high toxicity.

Concept of Nanotechnology in Drug Delivery

Nanocarriers are engineered materials designed to:

- Encapsulate or conjugate drugs
- Protect drugs from degradation
- Deliver drugs specifically to tumor sites

This approach enhances therapeutic efficacy while minimizing systemic side effects.

Types of Nanocarriers

1. Liposomes

- Spherical vesicles composed of lipid bilayers
- Suitable for both hydrophilic and hydrophobic drugs

2. Polymeric Nanoparticles

- Made from biodegradable polymers
- Provide controlled and sustained drug release

3. Solid Lipid Nanoparticles (SLNs)

- Improve drug stability and bioavailability

4. Dendrimers

- Highly branched structures with multiple functional groups
- Allow precise drug targeting

5. Metallic Nanoparticles

- Gold, silver nanoparticles used in imaging and therapy

Mechanism of Targeting

Passive Targeting

- Based on **Enhanced Permeability and Retention (EPR) effect**
- Tumor tissues allow accumulation of nanoparticles

Active Targeting

- Surface modification with ligands (antibodies, peptides)
- Specific binding to cancer cell receptors

Applications in Anticancer Therapy

- Targeted drug delivery to tumor cells
- Reduction in systemic toxicity
- Improved solubility of poorly soluble drugs
- Co-delivery of multiple drugs
- Use in gene therapy and immunotherapy

Advantages

- Enhanced drug bioavailability
- Site-specific drug delivery
- Controlled and sustained release
- Reduced side effects
- Improved patient compliance

Limitations

- Potential toxicity of nanomaterials
- High production cost
- Stability and scalability issues
- Regulatory challenges

7. ROLE OF SYNTHETIC CHEMISTRY [35–37]

Synthetic chemistry plays a central role in the discovery and development of anticancer drugs by enabling the **design, synthesis, and optimization of novel chemical entities**. It provides the foundation for generating structurally diverse compounds with improved biological activity, selectivity, and pharmacokinetic properties.

Importance in Drug Discovery

Synthetic chemistry contributes to:

- Creation of new molecular frameworks
- Modification of lead compounds
- Structure optimization for enhanced activity
- Development of scalable production methods

It bridges the gap between **computational predictions (QSAR, docking)** and **biological evaluation (cell line studies)**

Key Approaches in Synthetic Chemistry

1. Lead Optimization

- Structural modification of lead molecules to improve potency and selectivity
- Introduction of functional groups to enhance activity

2. Structure–Activity Relationship (SAR) Studies

- Systematic variation of chemical structure
- Identification of pharmacophoric features responsible for activity

3. Combinatorial Chemistry

- Rapid synthesis of large libraries of compounds
- High-throughput screening for anticancer activity

4. Green Chemistry Approaches

- Environmentally friendly synthesis methods
- Reduction of hazardous reagents and waste

5. Click Chemistry

- Efficient and selective reactions for rapid molecule assembly
- Widely used in drug conjugation and hybrid molecule synthesis

Applications in Anticancer Drug Design

- Synthesis of **heterocyclic compounds** with anticancer activity
- Development of **hybrid molecules** for multi-target action
- Design of **prodrugs** to improve bioavailability
- Preparation of compounds for **QSAR and docking studies**
- Generation of molecules for **in vitro evaluation (e.g., MCF-7 cell line studies)**

Advantages

- Enables structural diversity
- Facilitates precise molecular modifications
- Supports large-scale drug production
- Integrates with computational and biological studies

Challenges

- Complex and multi-step synthesis
- Time-consuming optimization process
- Cost of reagents and instrumentation
- Difficulty in scaling up certain reactions

Future Outlook

The future of anticancer drug design lies in the integration of multiple advanced technologies:

- AI-driven drug discovery platforms
- Combination therapies for synergistic effects
- Biomarker-based personalized treatments
- Green and sustainable synthesis methods

Continued research in these areas will lead to the development of **highly effective, safe, and patient-specific anticancer therapies**.

Conclusion

Next-generation strategies in anticancer drug design are transforming the landscape of cancer therapy. The integration of computational techniques, targeted therapy, nanotechnology, and synthetic chemistry provides a powerful framework for developing novel anticancer agents. These advancements hold great promise in overcoming the limitations of conventional treatments and improving patient outcomes.

8. SYNTHESIS OF NOVEL ANTICANCER COMPOUNDS

The design and synthesis of novel anticancer compounds play a crucial role in the development of effective therapeutic agents. Based on computational insights obtained from QSAR modeling and molecular docking studies, a series of structurally diverse compounds were rationally designed and synthesized.

The synthetic strategy involved conventional organic synthesis techniques, including condensation, cyclization, and substitution reactions, to obtain the desired chemical scaffolds. The synthesized compounds were purified using standard methods such as recrystallization and chromatography.

Further, the structural characterization of all synthesized compounds was carried out using advanced analytical techniques, including:

- Fourier Transform Infrared Spectroscopy (FT-IR)
- Proton Nuclear Magnetic Resonance (^{1}H NMR)
- Mass Spectrometry

These techniques confirmed the formation and purity of the synthesized molecules. The integration of computational design with synthetic chemistry ensured the development of compounds with potential biological activity and improved drug-like properties.

9. IN VITRO ANTICANCER ACTIVITY (CELL LINE STUDY)

The synthesized compounds were evaluated for their anticancer activity using the **MTT assay** against human cancer cell lines. The assay is based on the reduction of yellow tetrazolium salt (MTT) to purple formazan crystals by metabolically active cells, which reflects cell viability.

In the present study, the cytotoxic effects of the compounds were assessed on **MCF-7 (human breast cancer cell line)**. The cells were treated with varying concentrations (20–100 µg/mL) of the test compounds, and the percentage inhibition of cell viability was determined.

The results demonstrated a **dose-dependent increase in cytotoxic activity**, with higher concentrations showing greater inhibition of cell growth. The IC_{50} values were calculated to evaluate the potency of the compounds and compared with the standard drug. **[38-40].**

The findings indicate that the synthesized compounds exhibit **significant anticancer activity**, suggesting their potential as promising candidates for further development. However, additional studies such as:

- In vivo evaluation
- Mechanistic studies
- Toxicity profiling

are required to validate their therapeutic potential.

10. CONCLUSION

In conclusion, next-generation strategies in anticancer drug design represent a significant advancement over conventional therapies by addressing key challenges such as toxicity, drug resistance, and lack of selectivity. The integration of computational approaches like QSAR, molecular docking, and artificial intelligence with experimental techniques has accelerated the discovery and optimization of novel anticancer agents .

Furthermore, the development of targeted therapies, multi-target drugs, and nanotechnology-based delivery systems has enhanced treatment specificity and therapeutic efficacy while minimizing side effects. The successful synthesis and in vitro evaluation of novel compounds demonstrating dose-dependent anticancer activity highlight the potential of these approaches in real-world applications .

Overall, the combination of advanced drug design strategies with personalized medicine holds great promise for the future of cancer treatment. Continued research, along with in vivo and clinical validation, is essential to translate these findings into safe, effective, and patient-specific anticancer therapies.

11. FUTURE DIRECTIONS

The future of anticancer drug design is expected to evolve through the integration of advanced technologies and interdisciplinary approaches. Key future directions include:

- **AI-Driven Drug Discovery:**
  Increased use of artificial intelligence and machine learning to design novel molecules, predict drug–target interactions, and optimize lead compounds with higher accuracy and speed.
- **Personalized and Precision Medicine:**
  Development of patient-specific therapies based on genetic, proteomic, and biomarker profiling to improve treatment efficacy and reduce adverse effects.
- **Multi-Target and Combination Therapies:**
  Designing drugs that can simultaneously act on multiple cancer pathways or combining therapies to overcome drug resistance [11]and tumor heterogeneity.
- **Advanced Nanotechnology-Based Delivery Systems:**
  Development of smart nanocarriers for targeted, controlled, and stimuli-responsive drug delivery to enhance bioavailability and reduce systemic toxicity.
- **Integration of Omics Technologies:**
  Utilization of genomics, proteomics, and metabolomics for better understanding of cancer biology and identification of novel therapeutic targets.
- **Green and Sustainable Chemistry:**
  Adoption of eco-friendly synthesis methods to reduce environmental impact and improve scalability of drug production.
- **Translational and Clinical Research:**
  Emphasis on in vivo studies, clinical trials, and toxicity profiling to bridge the gap between laboratory findings and clinical application.
- **Immunotherapy and Gene-Based Approaches:**

Exploration of immune-modulating therapies and gene-editing technologies for more effective and long-lasting cancer treatment.

Overall, these future directions aim to develop safer, more effective, and highly targeted anticancer therapies, ultimately improving patient outcomes and quality of life.

12. STATEMENTS AND DECLARATIONS

Competing Interests: Authors declare no competing interests

Acknowledgments: The authors are thankful for providing necessary facilities for review work.

REFERENCES

1. Khaled DM, Elshakre ME, Noamaan MA, Butt H, Abdel Fattah MM, Gaber DA. A computational QSAR, molecular docking and cytotoxicity study of thiouracil-based anticancer agents. Int J Mol Sci. 2022;23(19):11799.
2. Altaf R, Nadeem H, Ilyas U, Iqbal J, Paracha RZ, Zafar H, et al. Cytotoxic evaluation, molecular docking, and QSAR studies of dihydropyrimidinone derivatives. J Oncol. 2022;2022:7715689.
3. Moussaoui M. Design and optimization of quinazoline derivatives as EGFR inhibitors using QSAR and molecular modeling. ACS Omega. 2024;9:45842–45857.
4. Aghayari S. Drug design of anticancer agents using QSAR modeling and molecular docking. Results Eng. 2025;106242.
5. Mkhayar K, Daoui O, Elkhattabi S, Chtita S, Elkhalabi R. QSAR and docking-assisted design of anticancer agents. Biointerface Res Appl Chem. 2023;13:524.
6. Mushtaq A, Wu P, Naseer MM. Recent drug design strategies and heterocyclic scaffolds for anticancer targets. Pharmacol Ther. 2024;254:108579.
7. Nguyen HD, Kim MS. Identification of inhibitory compounds using QSAR and docking approaches. Comput Biol Chem. 2023;104:107872.
8. Brown DG. Analysis of successful hit-to-clinical candidate drug pairs. J Med Chem. 2023;66(11):7101–7139.
9. Shi Y, Wu YR, Yu JQ, Zhang WN, Zhuang CL. DNA-encoded libraries in drug discovery. RSC Adv. 2021;11:2359–2376.
10. Bian Y, Xie XQ. Generative chemistry using deep learning for drug discovery. J Chem Inf Model. 2020;60:1–15.
11. Aqeel I. Machine learning and docking approaches for multitarget drug discovery. arXiv. 2024;2409.16486.
12. Vardhan S, Sahoo SK. In silico ADMET and docking studies for drug discovery. arXiv. 2020;2005.07955.
13. Martinez-Carmona M, Lozano D, Colilla M, Vallet-Regi M. Nanoparticle-based targeted drug delivery in cancer therapy. Nanomedicine. 2021;16:1–15.
14. Roma-Rodrigues C, Baptista PV, Fernandes AR. Nanomedicine in anticancer drug delivery. Molecules. 2020;25:1–25.
15. De Marco R, Mazzotti G, Greco A, Gentilucci L. Heterocyclic scaffolds in anticancer drug design. Eur J Med Chem. 2021;210:112993.
16. Zhang L, Zhang J, Chen L. Advances in AI-driven anticancer drug discovery. Brief Bioinform. 2022;23:bbac123.
17. Schneider G. Automating drug discovery with artificial intelligence. Nat Rev Drug Discov. 2020;19:353–364.
18. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing in cancer therapy. Nat Rev Drug Discov. 2020;19:673–689.
19. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails. Acta Pharm Sin B. 2022;12:304–318.
20. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2020;25:1–8.
21. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2021;73:1–35.
22. Dang Y, Guan J. Nanoparticle-based drug delivery systems in cancer therapy. Signal Transduct Target Ther. 2020;5:1–13.
23. Kaur G, Gupta V. Multi-target drug design strategies in cancer treatment. Curr Drug Targets. 2021;22:1–15.
24. Sharma A, Sharma R. Advances in QSAR modeling for anticancer drug design. Curr Top Med Chem. 2023;23:1–18.
25. Ibrahim MA, Abdelrahman MH. Quinoline-based anticancer agents and EGFR inhibition strategies. Eur J Med Chem. 2026;245:114897.
26. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.
27. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
28. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2020;25(2):1–8.
29. Wang Y, Liu X, Zheng Z, Zeng J, Zhang S. Advances in nanotechnology-based drug delivery systems for cancer therapy. J Nanobiotechnology. 2022;20:1–25.
30. Cheng L, Wang C, Feng L, Yang K, Liu Z. Functional nanomaterials for phototherapies of cancer. Chem Rev. 2020;120(4):1–52.
31. Li X, Wang Y, Wang Z. Targeted therapy for cancer: Current advances and future perspectives. Signal Transduct Target Ther. 2021;6:1–28.

32. Kuenzi BM, Ideker T. A census of pathway maps in cancer systems biology. Nat Rev Cancer. 2020;20:233–246.
33. Lavecchia A. Machine-learning approaches in drug discovery. J Med Chem. 2021;64(7):1–27.
34. Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, et al. Therapeutic target database update 2020. Nucleic Acids Res. 2020;48:D1031–D1041.
35. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy V, Aladinskaya A, et al. Deep learning enables rapid identification of drug candidates. Nat Biotechnol. 2020;38:1–10.
36. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2020;348(6230):56–61.
37. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano-based drug delivery systems: Recent developments. J Nanobiotechnology. 2021;19:1–33.
38. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2021;17:1–10.
39. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery. Nat Rev Drug Discov. 2021;20:1–18.
40. Kumar V, Singh A, Sharma R. Advances in heterocyclic compounds as anticancer agents. Bioorg Chem. 2023;132:106338.